AI has no boundaries, shaping a new era of intelligence | FANGZHOU JIANKE (06086) strategically partners with Shanghai Fosun Pharmaceutical (02196) to create a new intelligent ecosystem for psoriasis management.

On October 29, on the occasion of "World Psoriasis Day," the strategic cooperation signing ceremony between FANGZHOU JIANKE (06086) and Shanghai Fosun Pharmaceutical (02196) was grandly held in Shanghai. Dr. Xie Fangmin, founder, chairman, and CEO of FANGZHOU JIANKE, and Li Mei, Co-CEO of Shanghai Fosun Pharmaceutical's domestic marketing platform, along with the head of the new retail business unit Huang Jiaguo, jointly signed a strategic cooperation agreement. During the meeting, the two parties officially announced that they would closely collaborate in the "AI + chronic disease management" field, to jointly create a benchmark project in digital intelligence and further unleash the value of chronic disease management ecology. It was introduced that this strategic cooperation between the two parties will focus on autoimmune diseases such as psoriasis, and carry out in-depth academic, popular science, digital marketing, and other collaborations. Through the deep penetration of AI technology, it will realize AI empowerment in the full chain of chronic disease management from disease understanding, intervention to long-term services, and support the high-quality development of China's health industry. Psoriasis is a chronic, recurrent, and inflammatory disease that requires long-term standardized management. However, the traditional management model of psoriasis has always had pain points such as low patient compliance, difficult follow-ups outside the hospital, and the lack of personalized management plans. With the deep integration of AI technology and chronic disease management, it is now possible to provide precise assessment, personalized treatment, and long-term follow-up services for the complete disease management cycle of psoriasis through cutting-edge technology. By integrating the core capabilities of both sides, they bring better services to psoriasis patients. Shanghai Fosun Pharmaceutical will contribute its outstanding commercial platform capabilities, bringing innovative products for the treatment of psoriasis - Ortezla (apremilast tablets) and professional medical knowledge related to psoriasis. FANGZHOU JIANKE, on the other hand, will apply AI technology to the entire process of psoriasis management through its independently developed Xingshi medical model and the established "AI + H2H (Hospital To Home, from hospital to home) smart medical service new ecology". Specifically, the two parties will explore innovative paths for the full disease management cycle of psoriasis - FANGZHOU JIANKEAI Health Butlers will provide personalized rehabilitation advice and continuous tracking for patients; at the same time, the AI medication assistant can provide 24/7 medication consultation. When dealing with complex medication issues, platforms under FANGZHOU JIANKE can also match patients with professional medical consultants for in-depth answers and follow-ups to ensure the scientific and safety of the psoriasis management process. Li Mei, Co-CEO of Shanghai Fosun Pharmaceutical's domestic marketing platform, said: "The concepts of FANGZHOU JIANKE and Shanghai Fosun Pharmaceutical in chronic disease management are in line with each other. We look forward to relying on the company's innovative products and professional deposit in the field of psoriasis, along with FANGZHOU JIANKE's AI + H2H smart medical service new ecology, jointly building a systemic management system for patients. On this special day of caring for psoriasis patients, we are very pleased to be able to work together to promote such a far-reaching work for patients." Dr. Xie Fangmin, founder, chairman, and CEO of FANGZHOU JIANKE, said: "I am pleased to have reached a strategic cooperation with Shanghai Fosun Pharmaceutical, which is not only a sharing of resources but also marks the transition of our AI strategy from technological capability construction to the stage of creating value with industrial partners. Looking forward to using this cooperation as a good start, we will jointly create a new paradigm of 'AI+ psoriasis management' and expand this model to a more extensive range of diseases, benefiting more patients." After the signing ceremony, FANGZHOU JIANKE announced the official launch of the "AI+ Psoriasis Management New Vision" popular science publicity week. The publicity week uses AI technology to bring innovation and breakthroughs in the efficiency and quality of health popular science. On the first day of the live broadcast, it attracted over a million viewers, fully demonstrating the attractiveness of AI-empowered health popular science to the public. During this publicity week, a series of video live broadcasts will be provided to users. It is worth mentioning that AI capabilities will be integrated throughout the entire process - before the live broadcast, the platform will use AI technology to analyze the topics that users are concerned about and assist in precise content customization; during live interaction and follow-up services, AI technology will further optimize information dissemination and outreach efficiency, extending the immediate impact of single popular science to personalized long-term follow-up and accompanied management. This innovative practice drives health popular science from the previous one-way information dissemination to a user-centered, data-driven, and sustainable interactive new stage. This attempt not only significantly improves the public's health literacy and participation but also transforms health knowledge popular science touchpoints into continuous service entry points, providing strong support for expanding the depth and breadth of chronic disease management services. FANGZHOU JIANKE and Shanghai Fosun Pharmaceutical will use this cooperation in the field of psoriasis as a starting point to continuously deepen their strategic coordination in digital intelligence innovation, chronic disease management services, and other aspects. FANGZHOU JIANKE will also use this cooperation as a cornerstone to push its strategy to new heights, and the company's chronic disease management "AI+" ecological blueprint is accelerating. With the landing of benchmark projects such as AI+ weight loss and AI+ psoriasis, this innovative model will cover a wider range of chronic disease management fields in the future, contributing solid industrial strength to the construction of a healthy China.